Back to search results

Cognitive Remediation for Postviral Neurocognitive Dysfunction

This study is testing if a computerized "brain training" program called NeuroFlex can help older adults who have memory or thinking problems (neurocognitive dysfunction) after a viral infection like COVID-19. Participants will either use NeuroFlex, which trains basic processing and executive functions, or play other computer games that don't focus on these skills. The researchers want to see if NeuroFlex improves thinking abilities and daily functioning, and if these benefits last over time. They will measure changes in set-shifting abilities (how easily you can switch between tasks) and how easy the NeuroFlex program is to use. You might be able to join if you are 60 or older, had a confirmed COVID-19 infection, and have had cognitive symptoms for at least 12 weeks. The current status of this study is unclear.

Study design
This is a randomized study with two groups, planning to enroll 75 participants. Participants will be assigned to either the NeuroFlex program or an active control group.
What's involved
Participants will engage in a 6-week course of either computerized cognitive remediation or computer-based control activities. Measurements will be taken before treatment, after treatment (Week 7), and at 6 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 6 months after treatment to see if effects are maintained.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07171450

Cognitive Remediation

Recruiting
NAAges 60+InterventionalTreatment
Cutter Lindbergh
~75 participants
Updated 2026-02-24 on ClinicalTrials.gov
What's tested:Computerized Cognitive RemediationAlternative Computer Activities

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Group Difference in Set-Shifting Abilities at Post-Treatment as Measured with Trails B
Measured over Pre-treatment and post-treatment (Week 7)
+2 more outcomes measured

Conditions

Aging
Inflammation
Cognitive Remediation
Cognitive Dysfunction
Postviral Syndrome
Digital Medicine

Explore related trials

Cognitive Dysfunction

NCT07171450

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • UConn Health

    Farmington, Connecticutno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Cutter Lindbergh, Ph.D. · PRINCIPAL_INVESTIGATOR · UConn Health

Who to contact

Holly Eddy, Ph.D., LMFT-S
[email protected]
860-679-3751
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age ≥ 60 years old
prior history of COVID-19 that was confirmed with viral testing (e.g., positive laboratory test or positive at-home rapid test)
cognitive symptoms (e.g., memory or thinking concerns) following COVID- 19 infection that have lasted for at least 12 weeks and are still present
clinically meaningfully subjective cognitive concerns (i.e., T-score \< 40) on the PROMIS-Cognitive Function Scale
objective evidence of cognitive decline\*, as defined by performance on standardized measures of executive functioning, memory, or processing speed from the NIH Toolbox Cognition Battery that is at least 1 standard deviation below estimated premorbid cognitive functioning \[\*at least one third of the sample, or 25 out of 75 subjects, will be required to meet this inclusion criterion\]
fluent in English language
off psychiatric medication or on a stable dose for at least 8 weeks

Exclusion

history of neurological disorder with potential to interfere with study participation or confound results (e.g., uncontrolled seizure disorder, moderate to severe traumatic brain injury or stroke with persistent neurological deficits)
history of dementia and/or dementia range performance on the Mini- Mental State Examination (i.e., score of less than or equal to 23)
prior diagnosis of Mild Cognitive Impairment (MCI) or Mild Neurocognitive Disorder unrelated to the participant's history of COVID-19
history of severe psychiatric illness that may interfere with study participation or confound results (e.g., bipolar disorder, schizophrenia, or other psychotic disorder)
history of significant neurodevelopmental condition that may interfere with study participation or confound results (e.g., intellectual disability, autism spectrum disorder, or specific learning disorder with impairment in reading)
alcohol or other substance use disorder within the past 2 years
significant sensory impairments (e.g., blindness) that would interfere with the ability to complete neuropsychological measures or engage in the tablet-based intervention
performance that is below expectation on a test of effort and validity

What this trial measures

  • Group Difference in Set-Shifting Abilities at Post-Treatment as Measured with Trails BPre-treatment and post-treatment (Week 7)

    Part B of the Trail Making Test (Trails B) is an executive functioning measure of set-shifting abilities in which the examinee must rapidly alternate between connecting numbers and letters distributed across a page. The total time (in seconds) required for the examinee to complete the task is recorded. Lower scores (in seconds) indicate better performance. Time to complete Trails B at the post-treatment visit will be compared between treatment groups (i.e., NeuroFlex vs. Active Control Condition), controlling for pre-treatment Trails B performance.

  • Group Difference in Set-Shifting Abilities at 6 Months as Measured with Trails BPre-treatment and 6 Months

    Part B of the Trail Making Test (Trails B) is an executive functioning measure of set-shifting abilities in which the examinee must rapidly alternate between connecting numbers and letters distributed across a page. The total time (in seconds) required for the examinee to complete the task is recorded. Lower scores (in seconds) indicate better performance. Time to complete Trails B at the 6-month visit will be compared between treatment groups (i.e., NeuroFlex vs. Active Control Condition), controlling for pre-treatment Trails B performance.

  • User Experience/Interface with Computerized Cognitive Remediation Program at Post-Treatment as Measured with the System Usability ScalePost-Treatment (Week 7)

    The System Usability Scale is a well-validated, 10-item, self-report questionnaire of user experience/interface (UX/ UI) with computer-based programs. Participants rate each item using a 5-point Likert-style scale with response options ranging from "Strongly Disagree" to "Strongly Agree". Total scores ranging from 0-100 are calculated using a standard equation. Higher total scores indicate better UX/UI.